TNFRSF17 and plasma cell myeloma: For multiple myeloma (MM), the anti-BCMA (B cell maturation antigen) CARs, which are under extensive clinical development [32–34], have two issues: they could be rejected due to the presence of non-human sequences; there could be emergence of variants from loss of BCMA expression on the MM cells.